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Abstract
Background: The prescribing of psychotropic medicines for the paediatric population is rapidly increasing. In attempts 
to curb the use of psychotropic medicine in the paediatric population, regulatory authorities have issued various 
warnings about risks associated with use of these products in childhood. Little evidence has been reported about the 
adverse drug reactions (ADRs) of these medicines in practice. As spontaneous reports are the main source for 
information about previously unknown ADRs, we analysed data submitted to a national ADR database. The objective 
was to characterise ADRs reported for psychotropic medicines in the Danish paediatric population over a decade.
Findings: All spontaneous ADR reports from 1998 to 2007 for children from birth to 17 years of age were included. The 
unit of analysis was one ADR. We analysed the distribution of ADRs per year, seriousness, age and gender of the child, 
suspected medicine and type of reported ADR. A total of 429 ADRs were reported for psychotropic medicines and 56% 
of these were classified as serious. Almost 20% of psychotropic ADRs were reported for children from birth up to 2 years 
of age and one half of ADRs were reported in adolescents, especially for antidepressants and psychostimulants. 
Approximately 60% of ADRs were reported for boys. Forty percent of all ADRs were from the category 'nervous and 
psychiatric disorders'. All but one ADR reported for children below two years were serious and two of these were fatal. 
A number of serious ADRs reported in children from birth up to 2 years of age were presumably caused by mothers' 
use of psychotropic medicines during pregnancy.
Conclusion: The high number of serious ADRs reported for psychotropic medicines in the paediatric population 
should be a concern for health care professionals and physicians. Considering the higher number of birth defects 
being reported greater care has to be given while prescribing these drugs for pregnant women.
Background
The prescribing of psychotropic medicines for the paedi-
atric population is rapidly increasing in many countries
including Denmark. In attempts to curb the use of psy-
chotropic medicine in the paediatric population, regula-
tory authorities have issued various warnings about risks
associated with use of these products in childhood [1-4].
A systematic review detected seventeen studies since
2000 that reported information about the occurrence of
ADRs in paediatric populations [5]. Nearly one third of all
ADRs reported in children were due to psychotropic
medicines, especially CNS stimulants and antidepres-
sants. However, more detailed information about the
characteristics of ADRs from psychotropic medicines in
the general paediatric population is lacking and little evi-
dence has been reported about safety and long-term
effects of these medicines in practice [6-8]. Lack of
knowledge of adverse drug reactions (ADRs) at the point
of licensing of new medicines renders spontaneous ADR
reporting an important contributor to knowledge about
safety of medicines [9]. As spontaneous reports are the
main source for information about new and previous
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unknown ADRs we conducted an analysis of all sponta-
neous ADR reports for psychotropic medicines in Den-
mark from 1998 to 2007.
Methods
W e used data from the national Danish ADR database,
which contains information about all spontaneous
reports submitted to the Danish Medicines Agency
(DKMA) [10]. ADRs reported for children from 0 to 17
years of age were included. We analysed the distribution
of ADRs per year, seriousness, age and gender of the
child, suspected medicine and type of reported ADR (sys-
tem organ class [SOC]). ADRs were classified as serious
on the following criteria: death, life-threatening, requir-
ing hospitalisation or prolongation of existing hospitalisa-
tion, resulting in persistent or significant disability/
incapacity, a congenital anomaly/birth defect and other
medically important conditions.
Results
ADRs over time
From 1998 to 2007 a total of 2437 individual ADR reports
containing information about 4500 ADRs were reported
for children. Of these, 210 reports corresponding to 429
ADRs were submitted for psychotropic medicines. Figure
1 shows the annual distribution of the reported ADRs.
T h e r e  w e r e  w i d e  fl u c t u a t i o n s  i n  t h e  n u m b e r  o f  A D R s
reported annually, with an increase in number from 2003
to 2005 followed by a decrease in 2006 and 2007.
ADRs by age and seriousness
Table 1 shows the distribution of reported ADRs by ther-
apeutic group and medicine, age of patient and serious-
ness. Almost one fifth of ADRs were reported for
children below 2 years and one half of all ADRs were
reported for adolescents (from 11 to 17 years of age), and
45% of these were serious. Totally, 59% of all ADRs were
reported for boys. More than one half of all ADRs were
classified as 'serious'. Table 2 displays characteristics of
ADRs reported for children below two years. Two deaths
were reported for citalopram and fluoxetin due to chorio-
amnionitis and persistent foetal circulation, respectively.
ADRs among children up to 2 years of age encompassed a
wide range of reactions, e.g. convulsion, feeding disorder,
neonatal priapism, apnoea and ventricular septal defects.
Seven ADRs: drug exposure during pregnancy, neonatal
respiratory depression, apnoea and pallor were reported
as "maternal drugs affecting foetus". However, the
remaining ADRs were probably also caused by mothers'
use of psychotropic medicines during pregnancy, as the
indications for use were reported as depression, anxiety,
panic disorder and schizophrenia. The share of serious
psychotropic ADRs was higher than the share of serious
ADRs in Danish children in general (40%) [11]. In the
general Danish paediatric population, half of all ADRs
were reported in children from birth up to 2 years of age,
but for psychotropic medicines more than half of all
ADRs were reported for adolescents which reflect a more
extensive use of psychotropic medicine in 11 to 17- year-
Figure 1 Annual number of adverse drug reactions (ADRs) for psychotropic medicines reported in the Danish paediatric population.
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Table 1: Number of adverse drug reactions reported for psychotropic medication in the paediatric population by age and 
seriousness (in italic) (1998 to 2007)
Age groups (years) <1 1<2 2-10 11<17 Total
Antipsychotics (N05A)
Levomepromazine 1 (1) 001 2   (1)
Zipradison 0 0 2 16 (11) 18 (11)
Zuclopenthixol 1 (1) 00 1   (1) 2 (2)
C h l o r p r o t h i x e n e 00022
C l o z a p i n e 00011
Olanzapine 8 (8) 5 (5) 01 1   (3) 24 (16)
Quetiapine 1 (1) 01  ( 1) 14 (12) 16 (14)
Sulpiride 0 0 0 3 3
Risperidone 1 (1) 05 1 8   (5) 24 (6)
Aripiprazol 0 0 0 14 (3) 14 (3)
Total 12 (12) 5 (5) 8 (1) 81 (35) 106 (53)
Hypnotics and sedatives 
(N05B/N05C)
Diazepam 1 (1) 000 1   (1)
Oxazepam 3 (3)000 3   (3)
Buspirone 1 (1) 000 1   (1)
Chloral hydrate 0 0 3 (3) 03   (3)
Midazolam 0 0 1 (1) 2 (2) 3 (3)
Total 5 (5) 04   (4) 2 (2) 11 (11)
Antidepressants (N06A)
Imipramine 0 0 1 (1) 01   (1)
Clomipramine 1 (1) 000 1   (1)
Amitriptyline 2 (2) 000 2   (2)
Fluoxetine 14 (14) 00 1   (1) 15 (15)
Citalopram 17 (17) 4 (4) 5 (2) 10 (6) 36 (29)
Paroxetine 5 (4) 00 6   (2) 11 (6)
Sertralin 11 (11)0 9   (3) 25 (20) 45 (34)
Escitalopram 1 (1) 1 (1) 00 2   (2)
O x i t r i p t a n 00033
Mirtazapin 1 (1) 00 1 2   (8) 13 (9)
Venlafaxin 1 (1) 003 4   (1)
Total 53 (52) 5 (5) 15 (6) 60 (37) 133 (100)
Psychostimulants (N06B)
Methylphenidate 0 0 85 (35) 44 (17) 129 (52)
Modafinil 0 0 0 7 (7) 7 (7)
Atomoxetine 0 0 23 (7) 20 (11) 43 (18)
Total 0 0 108 (42) 71 (35) 179 (77)
Total N05 and N06 70 (69) 10 (10) 135 (53) 214 (109) 429 (241)Aagaard and Hansen BMC Research Notes 2010, 3:176
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Table 2: Serious ADRs from psychotropic medicines reported for children below two years of age (1998 to 2007)
ATC Medicines Adverse drug reaction No Indication of use Age ofchild
N05A Levopromazine Priapism 1 Headache 0
Olanzapine Atrial septal defects 1 NA 1
Blood glucose decreased 1 Schizophrenia 0
Convulsion 1 NA 0
Decreased appetite 1 Schizophrenia 0
Drug exposure during pregnancy 1 NA* 0
Failure to thrive 1 Schizophrenia 0
Feeding disorder, neonatal 1 Schizophrenia 0
Haemoglobin increased 1 NA 1
Hypoxia 1 NA 0
Pneumonia 1 NA 1
Polycythaemia 1 NA 1
Somnolence 1 Schizophrenia 0
Tension 1 NA 1
Risperidon Drug withdrawal syndrome, neonatal 1 Depression 0
Sulpirid Agitation, neonatal 1 Depression 0
Zuclopemthixol Supraventricular tachycardia 1 Schizophrenia 0
N05B Buspirone Ventricular septal defect 1 Depression 0
Diazepam Apnoea 1 Convulsions 0
Oxazepam Congenital acrochordon 1 Anxiety depression 0
Chondropathy 1 Anxiety depression 0
Drug exposure during pregnancy 1 Anxiety depression 0
N06A Amitriptyline Epilepsy 1 Depression 0
Febrile convulsion 1 Depression 0
Clompipramine Psychomotor retardation 1 NA 0
Citalopram Tremor, neonatal 3 Panic disorder 1
Drug withdrawal syndrome, neonatal 2 Depression/Panic disorder 0/1
Hypotonia, neonatal 2 Depression 0
Irritability 2 Panic disorder 0/1
Apnoea 1 NA* 0
Asthenia 1 NA 0
Chorioamnionitis 1 Depression 0
Convulsion, neonatal 1 Depression 0
Hypertonia 1 Panic disorder 1
Hypocalcaemia 1 Depression 0
Neonatal asphyxia 1 Depression 0
Neonatal respiratory depression 1 NA* 0
Oral candidiasis 1 Depression 0
Pallor 1 NA* 0
Premature labour 1 Depression 0
Ventricular septal defect 1 Depression 0
Escitalopram Atrial septal defect 1 NA 1
Drug exposure during pregnancy 1 NA* 0Aagaard and Hansen BMC Research Notes 2010, 3:176
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olds [9]. The majority of serious ADRs were reported in
infants in contrast to reports submitted to Health Canada
where 60% of all ADRs for psychotropic medicines were
reported in 13 to 19-year-olds, and only 12% in infants
[12]. A number of ADRs were reported for Danish chil-
dren below 2 years, probably due to the mother's intake of
psychotropic medicine, primarily antidepressants and
antipsychotics, during pregnancy. Serious ADRs such as
'neonatal withdrawal syndrome', 'ventricular septal
defects' and 'premature labour' were reported. The risks
of malformations as well as preterm delivery of babies
due to use of antidepressants during pregnancy have been
reported previously in the literature and is supported by
our results [13-16].
ADRs by therapeutic subgroups
The largest share of ADRs (42%) was reported for psy-
chostimulants (ATC group N06B), followed by 31% for
antidepressants (ATC group N06A) and 24% for antipsy-
chotics (ATC group N05A). More than one half of the
ADRs reported for antipsychotics were caused by the
drugs ziprasidone, olanzapine and risperidone. Although
only 2.5% of ADRs were reported for anxiolytics and sed-
atives (ATC group N05B and N05C), predominantly in
infants, all these ADRs were serious. Two-thirds of the
ADRs reported for antidepressants (ATC group N06A)
were reported for infants and adolescents and exclusively
for the medicines sertraline, citalopram and fluoxetine
and seventy-five percent of these were serious. For psy-
chostimulants (ATC group N06B) 50% of ADRs were
serious and reported for children from six to nine years of
age, and 40% of the reports were associated with meth-
ylphenidate and atomoxetine. With one exception, all 70
ADRs reported for children less than one year of age were
serious.
Fluoxetine Drug withdrawal syndrome, neonatal 3 Depression 0
Tremor 2 Depression 0
Agitation, neonatal 1 Depression 0
Bradycardia, neonatal 1 Depression 0
Deafness neurosensory 1 NA 0
Drug exposure during pregnancy 1 NA* 0
Dyskinesia, neonatal 1 Depression 0
Feeding disorder, neonatal 1 Depression 0
Hypertonia, neonatal 1 Depression 0
Neonatal disorder 1 Depression 0
Persistent foetal circulation 1 Depression 0
Upper limb deformity 1 Depression 0
Paroxetine Klinefelter's syndrome 1 NA 0
Neonatal respiratory failure 1 NA* 0
Psychomotor retardation 1 NA 0
Sertraline Respiration abnormal 2 Depression 0
Cerebral palsy 1 Depression 0
Circulatory collapse 1 Depression 0
Cyanosis 1 Depression 0
Drug withdrawal syndrome, neonatal 1 Depression 0
Drug exposure during pregnancy 1 Depression 0
Muscle spasms 1 Anxiety 0
Myoclonus 1 Anxiety 0
Persistent foetal circulation 1 Depression 0
Pulmonary hypertension 1 Depression 0
Mirtazapine Cerebral palsy 1 Depression 0
Venlafaxine Agitation, neonatal 1 Depression 0
*Indication for use not listed, but recorded as "Maternal drugs affecting foetus"; NA: not available
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ADRs by type
Table 3 shows the distribution of reported ADRs by sys-
tem organ class (SOC). The largest shares of ADRs were
r e p o r t e d  f o r  t h e  S O C s  ' p s y c h i a t r i c  d i s o r d e r s '  ( 2 0 %  o f
total), 'nervous system disorders' (20% of total) and 'gen-
eral disorders and administration site conditions' (12% of
total). Less than 1% of the total number of reports con-
cerned the following SOCs: 'ear and labyrinth disorders',
'endocrine disorders', 'hepatobiliary disorders', 'immune
system disorders', 'pregnancy, puerperium and perinatal
conditions' and 'surgical and medical procedures'. The
largest shares of serious ADRs, about 25% of all were
reported for the SOCs: 'psychiatric disorders' and 'ner-
vous system disorders'. The distribution between serious
and non-serious ADRs within SOCs varied. More than
seventy-five percent of ADRs reported from the SOCs:
'nervous system disorders', 'musculoskeletal and connec-
tive tissue disorders' and 'congenital, familial and genetic
disorders'were serious.
Implications
There are huge gaps in the evidence on the safety of med-
icines in children as only few medicines prescribed for
children are tested in clinical trials and licensed for use in
this population. In addition, information about serious
and long-term ADRs is sparse due to the limitations
embedded in the design of randomised, controlled clini-
cal trials which are used primarily to test hypotheses
about efficacy rather than safety and children are usually
excluded from clinical trials of medicines for ethical rea-
sons [17]. Therefore, it is very important to systematically
analyse and evaluate data reported to the spontaneous
reporting programmes as these reports are the major
source for new information about possibly serious and
previously unknown ADRs [18]. Several of the reported
ADRs were birth defects, an area where we have very lim-
ited knowledge.
Conclusions
The high number of serious ADRs reported for psycho-
tropic medicines in the paediatric population should be a
concern for health care professionals and physicians.
Considering the higher number of birth defects being
reported greater care has to be given while prescribing
these drugs for pregnant women.
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Table 3: Adverse drug reactions from psychotropic medicines by system organ class (descending order)
System Organ Class (SOC) All ADRs (%) Serious as % of all ADRs Serious as % of ADRs
N = 429 N = 241
Psychiatric disorders 20 25 70
Nervous system disorders 19 26 77
General disorders and administration site conditions 12 7 33
Skin and subcutaneous tissue disorders 8 3 21
Gastrointestinal disorders 8 6 41
Cardiac disorders 5 6 67
Investigations 5 6 67
Respiratory, thoracic and mediastinal breast disorders 4 4 59
Metabolism and nutrition disorders 3 2 38
Musculoskeletal and connective tissue disorders 3 4 77
Congenital, familial and genetic disorders 2 4 77
Reproductive system and breast disorders 2 1 22
Vascular disorders 2 2 56
Others 7 4 33Aagaard and Hansen BMC Research Notes 2010, 3:176
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